Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New drug combo shows promise for Hard-to-Treat cancers

NCT ID NCT04322006

First seen May 16, 2026 · Last updated May 21, 2026 · Updated 2 times

Summary

This study tested a new drug called TJ004309, alone or with another drug (Toripalimab), in 225 adults with advanced solid tumors that had stopped responding to standard treatments. The goal was to find the safest and most effective dose, and to check for side effects and early signs of tumor shrinkage. The study is now complete, and results help guide future research.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Locations

  • Army Medical Center of PLA

    Chongqing, Chongqing Municipality, China

  • Cancer Hospital affiliated to Shantou University Medical College

    Shantou, Guangdong, China

  • Cancer Hospital, Chinese Academy of Medical Sciences

    Beijing, Beijing Municipality, China

  • Chongqing Cancer Hospital

    Chongqing, Chongqing Municipality, China

  • Fudan University Shanghai Cancer Center

    Shanghai, Shanghai Municipality, 200032, China

  • Guangdong Provincial Hospital of Chinese Medicine

    Guangzhou, Guangdong, China

  • Guangdong Provincial People's Hospital

    Guangzhou, Guangdong, 510080, China

  • Harbin Medical University Cancer Hospital

    Haerbin, Heilongjiang, China

  • Henan Cancer Hospital

    Zhengzhou, Henan, China

  • Hubei Cancer Hospital

    Wuhan, Hubei, China

  • Hunan Cancer Hospital

    Changsha, Hunan, China

  • Liaoning Cancer Hospital and Institute

    Shenyang, Liaoning, China

  • Northern Jiangsu People's Hospital

    Yangzhou, Jiangsu, China

  • Sichuan Cancer Hospital

    Chengdu, Sichuan, China

  • Sir Run Run Shaw Hospital, Zhejiang University School of Medicine

    Hanzhou, Zhejiang, China

  • The First Affiliated Hospital of Anhui Medical University

    Hefei, Anhui, China

  • The First Affiliated Hospital of Guangxi Medical University

    Nanning, Guangxi, China

  • The First Affiliated Hospital of Xi 'an Jiaotong University

    Xi'an, Shaanxi, China

  • The First Bethune Hospital of Jilin University

    Changchun, Jilin, 130021, China

  • The First Hospital of China Medical University

    Shenyang, Liaoning, China

  • The Second Affiliated Hospital of Nanchang University

    Nanchang, Jiangxi, China

  • Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

    Wuhan, Hubei, China

  • Yunnan Cancer Hospital

    Kunming, Yunnan, China

Conditions

Explore the condition pages connected to this study.